Evidence map›Paper›PMID 29522575›Full record

ArticlePLoS pathogens2018

Lung macrophage scavenger receptor SR-A6 (MARCO) is an adenovirus type-specific virus entry receptor.

Nicole Stichling, Maarit Suomalainen, Justin W Flatt, Markus Schmid, Martin Pacesa, Silvio Hemmi, Wolfgang Jungraithmayr, Mareike D Maler, Marina A Freudenberg, Andreas Plückthun and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Nicole StichlingDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7619-5612
Maarit SuomalainenDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3276-3008
Justin W FlattDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
Markus SchmidDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4533-371X
Martin PacesaDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1560-5769
Silvio HemmiDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4238-2217
Wolfgang JungraithmayrUniversity Hospital Zurich, Institute of Thorax Surgery, Zurich, Switzerland.
Mareike D MalerMax-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.ORCID 0000-0002-8642-3287
Marina A FreudenbergMax-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Andreas PlückthunDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-4191-5306
Tobias MayInscreenex GmbH, Inhoffenstr. Brunswick, Germany.ORCID 0000-0002-4042-4815
Mario KösterHelmholtz-Zentrum für Infektionsforschung GmbH, Braunschweig, Germany.
György FejerSchool of Biomedical and Healthcare Sciences, Peninsula Schools of Medicine and Dentistry, University of Plymouth, Plymouth, United Kingdom.ORCID 0000-0001-6761-0506
Urs F GreberDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-2278-120X
University of Zurich · CHUniversity of Freiburg · DEHelmholtz Centre for Infection Research · DEPeninsula College of Medicine and Dentistry · GBUniversity Hospital of Zurich · CH

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L00058X/1
6 · The paper itself

Abstract

Macrophages are a diverse group of phagocytic cells acting in host protection against stress, injury, and pathogens. Here, we show that the scavenger receptor SR-A6 is an entry receptor for human adenoviruses in murine alveolar macrophage-like MPI cells, and important for production of type I interferon. Scavenger receptors contribute to the clearance of endogenous proteins, lipoproteins and pathogens. Knockout of SR-A6 in MPI cells, anti-SR-A6 antibody or the soluble extracellular SR-A6 domain reduced adenovirus type-C5 (HAdV-C5) binding and transduction. Expression of murine SR-A6, and to a lower extent human SR-A6 boosted virion binding to human cells and transduction. Virion clustering by soluble SR-A6 and proximity localization with SR-A6 on MPI cells suggested direct adenovirus interaction with SR-A6. Deletion of the negatively charged hypervariable region 1 (HVR1) of hexon reduced HAdV-C5 binding and transduction, implying that the viral ligand for SR-A6 is hexon. SR-A6 facilitated macrophage entry of HAdV-B35 and HAdV-D26, two important vectors for transduction of hematopoietic cells and human vaccination. The study highlights the importance of scavenger receptors in innate immunity against human viruses.

Indexed as

Virus InternalizationAdenoviridae InfectionsAdenoviruses, HumanAnimalsHumansImmunity, InnateLungMacrophagesMacrophages, AlveolarMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutProtein BindingReceptors, ImmunologicMARCO protein, humanMarco protein, mouseReceptors, Immunologic

Identifiers

PMID29522575
PMCPMC5862501
OpenAlexW2793047198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.